Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases

Respirology

Volumn 21, Issue 2, 2016, Pages 363-369

  Özvatan, Tülay ^a   Akalin, Halis ^a   Sinirtaş, Melda ^a   Ocakoʇlu, Gökhan ^a   Yilmaz, Emel ^a   Heper, Yasemin ^a   Kelebek, Nermin ^a   Işçimen, Remzi ^a   Kahveci, Ferda ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Acinetobacter baumannii; colistin; nosocomial pneumonia; pneumonia; ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFOPERAZONE PLUS SULBACTAM; COLISTIMETHATE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; RIFAMPICIN; SULTAMICILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS-BAUMANNII COMPLEX; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIAL STRAIN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTECTION; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SEPTIC SHOCK; TURKEY (REPUBLIC); VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; AGED; CROSS INFECTION; MICROBIOLOGY; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; SEVERITY OF ILLNESS INDEX;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 84955318502     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12698     Document Type: Article

References (50)

1. Bergogne-Berezin E, Towner KJ,. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 1996; 9: 148-165.
2. Luna CM, Aruj PK,. Nosocomical Acinetobacter pneumonia. Respirology 2007; 12: 787-791.
3. Munoz-Price LS, Weinstein RA,. Acinetobacter infection. N. Engl. J. Med. 2008; 358: 1271-1281.
4. Peleg AY, Seifert H, Paterson DL,. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 2008; 21: 538-582.
5. Playford EG, Craig JC, Iredell JR,. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J. Hosp. Infect. 2007; 65: 204-211.
6. Fournier PE, Richet H,. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 2006; 42: 692-699.
7. Viehman JA, Nguyen MH, Doi Y,. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 2014; 74: 1315-1333.
8. Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP,. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. BioMed Res. Int. 2014; 2014: 305784.
9. Kim UJ, Kim HK, An JH, Cho SK, Park KH, Jang HC,. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J 2014; 50: 37-44.
10. Bone R, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus MA, Schein RM, Sibbald WJ,. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
11. Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA,. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-1624.
12. Kwa AL, Low JG, Lee E, Kurup A, Chee HL, Tam VH,. Low the impact of multidrug resistance on the outcomes of critically ill patients with gram-negative bacterial pneumonia. Diagn. Microbiol. Infect. Dis. 2007; 58: 99-104.
13. Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A,. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir. Med. 2006; 100: 1554-1565.
14. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P,. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J. Antimicrob. Chemother. 2006; 57: 1251-1254.
15. Wareham DW, Bean DC, Khanna P, Hennesy EM, Krahe D, Ely A, Millar M,. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 607-612.
16. Choi JY, Park YS, Kim CO, Park YS, Yoon HJ, Shin SY, Kim YA, Song YG, Yong D, Lee K, et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern. Med. J. 2005; 35: 599-603.
17. Blot S, Vandewoude K, Colardyn F,. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med. 2003; 29: 471-475.
18. Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, Palizas F, Menga G, Rios F, Apeztequia C,. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit. Care Med. 2003; 31: 676-682.
19. Sinirtaş M, Akalin H, Gedikoʇlu S,. Investigation of colistin sensitivity via three different methods in Acinetobacter baumannii isolates with multiple antibiotic resistance. Int. J. Infect. Dis. 2009; 13: e217-220.
20. Ye JJ, Lin HS, Kuo AJ, Leu HS, Chiang PC, Huang CT, Lee MH,. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J. Infect. 2011; 63: 351-361.
21. Falagas ME, Bliziotis IA, Siempos II,. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit. Care 2006; 10: R48.
22. Dizbay M, Tunccan ÖG, Sezer BE, Hbox drawings light down and leftzel K,. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand. J. Infect. Dis. 2010; 42: 741-746.
23. Chang HC, Chen YC, Lin MC, Liu SF, Chung YH, Su MC, Fang WF, Tseng CC, Lie CH, Huang TH, et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. J. Formos. Med. Assoc. 2011; 110: 564-571.
24. Chan JD, Graves JA, Dellit TH,. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J. Intensive Care Med. 2010; 25: 343-348.
25. Kalin G, Alp E, Akin A, Coskun R, Doʇanay M,. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 2014; 42: 37-42.
26. Aydemir H, Akduman D, Piskin N, Cömert F, Horuz E, Terzi A, Köktürk T, Çelebi G,. Colistin vs. combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol. Infect. 2013; 141: 1214-1222.
27. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME,. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J. Infect. 2013; 66: 401-414.
28. Falagas ME, Rafailidis PI,. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit. Care 2007; 11: 134.
29. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J,. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients.: a matched cohort study. Crit. Care Med. 2003; 31: 2478-2482.
30. Joung MK, Kwon KT, Kang CI, Cheong HS, Rhee JY, Jung DS, Chung SM, Lee JA, Moon SY, Ko KS, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J. Infect. 2010; 61: 212-218.
31. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabo-Pallas T, Cayuela A, Marquez-Vacera JA, Garcia-Cuniola A, Jimenez-Jimenez FJ,. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005; 31: 649-655.
32. Gurjar M, Saigal S, Baronia AK, Rao BP, Azim A, Poddar B, Singh RK,. Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: clinical characteristics and outcome. Indian J. Crit. Care Med. 2013; 17: 129-134.
33. Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A,. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int. J. Antimicrob. Agents 2014; 43: 378-382.
34. Simsek F, Gedik H, Ybox drawings light down and leftldbox drawings light down and leftrmak MT, Iris NE, Türkmen A, Ersoy A, Ersöz M, Gücüyener A,. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy? Indian J. Med. Microbiol. 2012; 30: 448-452.
35. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI, Aydemir S, Bacakoglu F,. Is tigecycline a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia? J. Chemother. 2011; 23: 345-349.
36. Micek ST, Reichley RM, Kollef MH,. Health care-associated pneumonia(HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine (Baltimore) 2011; 90: 390-395.
37. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Joly EC,. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-685.
38. Alvarez-Lerma F,. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996; 22: 387-394.
39. Rello J, Gallego M, Mariscal D, Sonora R, Valles J,. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 1997; 156: 196-200.
40. Zheng YL, Wan YF, Zhou LY, Ye ML, Liu S, Xu CQ, He YQ, Chen JH,. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am. J. Infect. Control 2013; 41: e59-63.
41. Mai MH, Tsai HC, Lee SS, Wang YH, Chen YS, Wann SR, Liu YC,. Multidrug-resistant Acinetobacter baumannii in ventilator-associated pneumonia at a medical center in southern Taiwan. J. Microbiol. Immunol. Infect. 2007; 40: 401-405.
42. Livermore DM, Hill RL, Thomson H, Charlett A, Turban JF, Pike R, Patel BC, Manuel R, Gillespie S, Balakrishnan I, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int. J. Antimicrob. Agents 2010; 35: 19-24.
43. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ,. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 2007; 60: 317-322.
44. Garonzik SM, Li J, Thamlikitful V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL,. Population pharmacokinetics of colistin methansulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 2011; 55: 3284-3294.
45. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antaniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 2009; 53: 3430-3436.
46. Xia J, Zhang D, Xu Y, Gong M, Zhou Y, Fang X,. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam. Int. J. Infect. Dis. 2014; 23: 90-93.
47. Chaari A, Mnif B, Bahloul M, Mahjoubi F, Chtara K, Turki O, Gharbi N, Chelly H, Hammami A, Bouaziz M,. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int. J. Infect. Dis. 2013; 17: e1225-e-8.
48. Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW,. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J. Med. Assoc. Thai. 2011; 94: 863-870.
49. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW,. Bloodstream infections caused by antibiotic-resistant gram negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother. 2005; 49: 760-766.
50. Leroy O, Meybeck A, D'Escrivan T, Devos P, Kipnis E, Georges H,. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med. 2003; 29: 2170-2173.